Onco Actu du 25 mai 2020

	1.4 BIOLOGIE - TECHNOS, MODÈLES
Bezos, Paul Allen funds, a16z put up $100M to build an Illumina of human proteins [EndPoints] Unlike other proteomics that have recently launched, such as Seer or SomaLogic, Nautilus has no intention of bringing forward any of its own drugs or diagnostics. Instead it will use itself as a platform that other research labs can access to run analyses, first by sending out samples to Nautilus and eventually by buying a machine.
	4. DÉPISTAGE, DIAGNOSTIC ET PRONOSTIC
Deep learning accurately stains digital biopsy slides [MIT] Pathologists who examined the computationally stained images could not tell them apart from traditionally stained slides.
	4.1 DÉP., DIAG. & PRONO. - PROSTATE
New Research Reveals Potentially Treatable Genetic Mutations in Patients Resistant to PSMA-Targeting Therapy [SNMMI] In an exploratory study using a relatively new technique—targeted next-generation gene sequencing—researchers found mutations in six out of seven patients with metastatic castration-resistant prostate cancer who did not respond to prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical therapy despite sufficient PSMA expression in their tumors.
	4.3 DÉP., DIAG. & PRONO. - INDUSTRIELS
Roche acquires Stratos Genomics to further develop DNA based sequencing for diagnostic use [Roche] This investment complements the development of Roche’s nanopore technology with the goal of an end-to-end sequencing solution starting from a patient sample to a diagnostic result.
Myriad Receives FDA Approval of BRACAnalysis CDx® as a Companion Diagnostic for Lynparza® in HRR-mutated Metastatic Castration-Resistant Prostate Cancer [Myriad] “This approval is our seventh regulatory approval for BRACAnalysis CDx in support of Lynparza and further demonstrates our commitment to improve the lives of patients with cancer.”
	4.7 DÉP., DIAG. & PRONO. - COL DE L'UTÉRUS
All women should have access to the at-home test that can provide early detection of cervical cancer [STAT] The HPV self-collection test I’ve used in my research in both rural Virginia and Nicaragua makes it possible for women to collect their own cervical sample in the privacy of their homes and mail to a lab to be tested.
	5.1 TRAITEMENTS - PRÉ-CLINIQUE
New Liver Cancer Research Targets Non-Cancer Cells to Blunt Tumor Growth [Penn Medicine] By targeting senescent cells using “senotherapy” researchers can greatly reduce tumors in models.
	5.10 TRAITEMENTS - ESSAIS
Patients with Metastatic Pancreatic Cancer and DNA Repair Defects May Have Improved Survival after Platinum-based Chemotherapy [AACR] In this study, Park, O’Reilly, and colleagues analyzed the association between mutations in HR genes and clinical outcome. The study included 262 patients with metastatic pancreatic cancer, who underwent both germline and somatic sequencing using the MSK-IMPACT sequencing test.
	5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES
WuXi upgrades CAR-T offerings with new manufacturing platform [Fierce Pharma] CAR-T is a particularly hot field in the oncology arena, as last week’s abstract release for the upcoming American Society of Clinical Oncology virtual annual meeting exemplified. But when it comes to taking drugs from development to market, drugmakers so far have stumbled on account of the complex manufacturing processes required to reprogram patients’ cells.
	5.12.5 IMMUNOTHÉRAPIES - PHARMA
European Medicines Agency Validates Bristol Myers Squibb’s Applications for Idecabtagene Vicleucel (Ide-cel, bb2121) and CC-486 [BMS] Applications based on positive results from pivotal KarMMa study in relapsed and refractory multiple myeloma and QUAZAR®-AML-001 study in acute myeloid leukemia.
	5.12.7 IMMUNOTHÉRAPIES - VACCINS
Researchers Develop High-performance Cancer Vaccine Using Novel Microcapsules [Chinese Academy of Sciences] Scientists have developed a new therapeutic tumor vaccine based on self-healing polylactic acid microcapsules, which can efficiently activate the immune system and inhibit tumor development. This research was published in Science Advances on May 22.
	5.12.8 IMMUNOTHÉRAPIES - ECONOMIE
Improved deal means new treatment for a type of advanced breast cancer can be recommended by NICE [NICE] The positive recommendation follows consultation on NICE’s previous draft guidance which did not recommend atezolizumab. The company has agreed to provide a larger discount to the list price of the drug following a deal with NHS England & NHS Improvement.
	5.2 PHARMA
Enhertu granted Orphan Drug Designation in the US for gastric cancer [AstraZeneca] Designation follows recent US Breakthrough Therapy Designations for Enhertu for HER2-positive metastatic gastric cancer and HER2-mutant metastatic non-small cell lung cancer.
	5.2.6 PHARMA - BIOTECH
Day One debuts with $60M to change cancer care—starting with children [Fierce Biotech] Its first program? A RAF inhibitor from Sunesis Pharma that was previously licensed by Takeda. Day One is developing DAY101, previously called TAK-580, as a targeted treatment for children with brain cancer.
A new biotech from a longtime developer wants to bring the targeted cancer revolution to the kids left behind [EndPoints] The company, called Day One, has raised $60 million from Atlas, Canaan, and others behind a vision of finding shelved and other drugs with promise for kids, licensing and bringing them forward. They’re starting with TAK-580, an old Takeda therapy they’re now testing in children with gliomas.
	5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)
U.S. FDA Approves Takeda’s ALUNBRIG® (brigatinib) as a First-Line Treatment Option for Patients Diagnosed with Rare and Serious Form of Lung Cancer [Takeda] Long-Term Results from the Phase 3 ALTA 1L Trial Established ALUNBRIG as a Superior First-Line Treatment Compared to Crizotinib for People with ALK+ Metastatic NSCLC, Including those with Brain Metastases.
AstraZeneca, Merck push blockbuster franchise to another key FDA approval, relegating a rival to second-fiddle status [EndPoints] Rubraca’s approval encompasses patients only with BRCA mutation-associated mCRPC, and is yet to show an impact on overall survival, although a study designed to measure that metric is ongoing.
	5.5.1.1 ASCO (GÉNÉRAL) - INDUSTRIELS
GSK highlights scientific innovation and advances in its growing oncology portfolio at ASCO 2020 [GSK] 26 abstracts across 8 tumour types, advancing GSK’s goal of maximising outcomes for patients.
	5.5.17 ASCO (PANCRÉAS)
UC study shows promising results for cancer treatment [University of Cincinnati] New results show chemotherapy prior to surgery may help outcomes for patients with pancreatic cancer.
	5.6.6 ESMO - SEIN
ESMO Breast Cancer Virtual Meeting 2020: Results of an Interim Analysis of the PHranceSCa Study [ESMO] Patients with HER2-positive early breast cancer prefer a subcutaneous fixed-dose combination of pertuzumab and trastuzumab over intravenous treatment.
ESMO Breast Cancer Virtual Meeting 2020: Final Results of the LOTUS Study [ESMO] Findings from the phase II study support further evaluation of ipatasertib plus paclitaxel in patients with advanced triple-negative breast cancer.
Novel Biomarkers Predict Benefit with Immunotherapy in Metastatic Breast Cancer [ESMO] To explore new potential biomarkers for immunotherapy in advanced breast cancer, researchers assessed the predictive value of copy number alteration (CNA) for the PDL1 gene, which measures whether the gene number has decreased, remained the same (2 copies, one on each chromosome) or increased.
	5.9.3 EHA
Bristol Myers Squibb Research at EHA 2020 Demonstrates Continued Advances Across Multiple Blood Diseases [BMS] Data from multiple studies, including results in the outpatient administration setting and using machine learning technology, evaluating potential of CAR T liso-cel in relapsed and refractory large b-cell lymphoma.
	6. LUTTE CONTRE LES CANCERS
New Cancer Cachexia Guideline Addresses Common Quality-of-Life Issue [ASCO] The guideline is the result of a literature review that included 20 systematic reviews and 13 randomized clinical trials. An Expert Panel was convened to evaluate this available evidence and formulate recommendations.
NCI BSA approves 11 new and reissue concepts, defers one [The Cancer Letter] The Board of Scientific Advisors voted to defer one concept, “Low-dose CT Lung Cancer Screening Image and Data Resource,” to a future meeting.
	6.1 OBSERVATION
Advanced prostate cancer rates continued to rise after guideline change [Medical XPress] The study, led by American Cancer Society investigators, says the rise in cancers that had spread beyond the prostate gland was accompanied by drops in early-stage disease during the same time period. The study appears in JNCI, the Journal of the National Cancer Institute.
	6.15 LUTTE CONTRE LES CANCERS - COVID-19
A telesitevisit: Cancer center site visits go virtual amid COVID-19 pandemic [The Cancer Letter] Virtual site visits are a new thing. So, how does NCI transport a multi-day in-person visit, as well as multiple teams, presentations, and discussions, into the Zoomiverse?
How Does COVID-19 Affect People with Cancer? NCCAPS Will Help Find Out [NCI] The study is now open to adults who are getting tested for or have COVID-19 and are also undergoing cancer treatment. We plan to expand the study later to include children with cancer and COVID-19.
	6.6 PUBLICATIONS, POLITIQUES SCIENTIFIQUES
Will Trump White House tear down journal paywalls? Many anxiously await a decision [Science] Although it appears the White House can impose a new policy without going through a formal rulemaking process, which would involve collecting more public comment, it’s possible that Congress could also get involved, particularly if lawmakers don’t like the change.